Q32 Bio Inc. (QTTB)

Market Cap	316.61M
Revenue (ttm)	1.16M
Net Income (ttm)	-112.96M
Shares Out	11.93M
EPS (ttm)	-35.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,771
Open	27.01
Previous Close	27.40
Day's Range	25.90 - 27.38
52-Week Range	8.24 - 30.92
Beta	n/a
Analysts	Buy
Price Target	47.50 (+78.98%)
Earnings Date	May 14, 2024

About QTTB

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 37
• Stock Exchange: NASDAQ
• Ticker Symbol: QTTB

Financial Performance

In 2023, Q32 Bio's revenue was $1.16 million, a decrease of -63.97% compared to the previous year's $3.21 million. Losses were -$112.96 million, 2157.0% more than in 2022.

Financial numbers in USD

Analyst Forecast

According to 2 analysts, the average rating for QTTB stock is "Buy." The 12-month stock price forecast is $47.5, which is an increase of 78.98% from the latest price.

Price Target

$47.5

(78.98% upside)

Analyst Consensus: Buy